162 related articles for article (PubMed ID: 21388298)
1. CMY-42, a novel plasmid-mediated CMY-2 variant AmpC beta-lactamase.
Hentschke M; Kotsakis SD; Wolters M; Heisig P; Miriagou V; Aepfelbacher M
Microb Drug Resist; 2011 Jun; 17(2):165-9. PubMed ID: 21388298
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A
Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital.
Briñas L; Lantero M; de Diego I; Alvarez M; Zarazaga M; Torres C
J Antimicrob Chemother; 2005 Dec; 56(6):1107-10. PubMed ID: 16239288
[TBL] [Abstract][Full Text] [Related]
4. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
[TBL] [Abstract][Full Text] [Related]
5. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway.
Naseer U; Haldorsen B; Simonsen GS; Sundsfjord A
Clin Microbiol Infect; 2010 Feb; 16(2):171-8. PubMed ID: 19548922
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype.
Jørgensen RL; Nielsen JB; Friis-Møller A; Fjeldsøe-Nielsen H; Schønning K
J Antimicrob Chemother; 2010 Mar; 65(3):460-4. PubMed ID: 20097787
[TBL] [Abstract][Full Text] [Related]
7. Increased Hydrolysis of Oximino-β-Lactams by CMY-107, a Tyr199Cys Mutant Form of CMY-2 Produced by Escherichia coli.
Kotsakis SD; Miriagou V; Vetouli EE; Bozavoutoglou E; Lebessi E; Tzelepi E; Tzouvelekis LS
Antimicrob Agents Chemother; 2015 Dec; 59(12):7894-8. PubMed ID: 26438499
[TBL] [Abstract][Full Text] [Related]
8. Emergence of CMY-2-Producing Escherichia coli in Korean Layer Parent Stock.
Seo KW; Shim JB; Lee YJ
Microb Drug Resist; 2019 Apr; 25(3):462-468. PubMed ID: 30625027
[TBL] [Abstract][Full Text] [Related]
9. Comparison of broad-spectrum cephalosporin-resistant Escherichia coli isolated from dogs and humans in Hokkaido, Japan.
Okubo T; Sato T; Yokota S; Usui M; Tamura Y
J Infect Chemother; 2014 Apr; 20(4):243-9. PubMed ID: 24709044
[TBL] [Abstract][Full Text] [Related]
10. Two novel CMY-2-type β-lactamases encountered in clinical Escherichia coli isolates.
Manageiro V; Ferreira E; Pinto M; Fonseca F; Ferreira M; Bonnet R; Caniça M
Ann Clin Microbiol Antimicrob; 2015 Mar; 14():12. PubMed ID: 25885413
[TBL] [Abstract][Full Text] [Related]
11. Evidence for transfer of CMY-2 AmpC beta-lactamase plasmids between Escherichia coli and Salmonella isolates from food animals and humans.
Winokur PL; Vonstein DL; Hoffman LJ; Uhlenhopp EK; Doern GV
Antimicrob Agents Chemother; 2001 Oct; 45(10):2716-22. PubMed ID: 11557460
[TBL] [Abstract][Full Text] [Related]
12. Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment.
Pitout JD
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1165-76. PubMed ID: 23199402
[TBL] [Abstract][Full Text] [Related]
13. Characterization of blaCMY-11, an AmpC-type plasmid-mediated beta-lactamase gene in a Korean clinical isolate of Escherichia coli.
Lee SH; Kim JY; Lee GS; Cheon SH; An YJ; Jeong SH; Lee KJ
J Antimicrob Chemother; 2002 Feb; 49(2):269-73. PubMed ID: 11815567
[TBL] [Abstract][Full Text] [Related]
14. Emergence of a cefepime- and cefpirome-resistant Citrobacter freundii clinical isolate harbouring a novel chromosomally encoded AmpC beta-lactamase, CMY-37.
Ahmed AM; Shimamoto T
Int J Antimicrob Agents; 2008 Sep; 32(3):256-61. PubMed ID: 18619820
[TBL] [Abstract][Full Text] [Related]
15. Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli.
Odeh R; Kelkar S; Hujer AM; Bonomo RA; Schreckenberger PC; Quinn JP
Clin Infect Dis; 2002 Jul; 35(2):140-5. PubMed ID: 12087519
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of CMY-2 producing E. coli in a broiler parent flock.
Dame-Korevaar A; Fischer EAJ; Stegeman A; Mevius D; van Essen-Zandbergen A; Velkers F; van der Goot J
Vet Microbiol; 2017 May; 203():211-214. PubMed ID: 28619146
[TBL] [Abstract][Full Text] [Related]
17. Expansive spread of IncI1 plasmids carrying blaCMY-2 amongst Escherichia coli.
Sidjabat HE; Seah KY; Coleman L; Sartor A; Derrington P; Heney C; Faoagali J; Nimmo GR; Paterson DL
Int J Antimicrob Agents; 2014 Sep; 44(3):203-8. PubMed ID: 25052868
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan.
Matsumura Y; Yamamoto M; Higuchi T; Komori T; Tsuboi F; Hayashi A; Sugimoto Y; Hotta G; Matsushima A; Nagao M; Takakura S; Ichiyama S
Int J Antimicrob Agents; 2012 Aug; 40(2):158-62. PubMed ID: 22743014
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic trapping by plasmid-encoded CMY-2 β-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli.
Goessens WH; van der Bij AK; van Boxtel R; Pitout JD; van Ulsen P; Melles DC; Tommassen J
Antimicrob Agents Chemother; 2013 Aug; 57(8):3941-9. PubMed ID: 23733461
[TBL] [Abstract][Full Text] [Related]
20. CMY-20, a novel AmpC-type beta-lactamase from South African clinical Escherichia coli isolates.
Mocktar C; Govinden U; Sturm AW; Essack SY
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):405-8. PubMed ID: 18207348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
